Merck to strengthen work for cardio health
Subsequent to the completed $41 billion merger with Schering-Plough, Merck said today that it will continue its research to expand and market treatments for cardiovascular disorders.
Whitehouse Station, N.J.-based Merck said it will use “integrated genomics” and “experimental medicine” to link similarities of heart disease and other disorders such as diabetes and metabolic syndrome.
According to the company, its six current clinical studies are being conducted on 90,000 patients in 40 countries to help progress treatments for cardiovascular diseases.
In addition, Merck also has developed prescription medication to aid in the treatment of various cardiovascular diseases and has provided 1.5 million prescriptions to patients who had financial hardships or were uninsured in 2008 through its patient assistance program (PAP).
Merck agreed to strengthen its ties with Actelion, Cardiome, Arena, Mochida, Portola and Xenon Pharmaceuticals to continue its assistance in the progression of cardiovascular care.
Whitehouse Station, N.J.-based Merck said it will use “integrated genomics” and “experimental medicine” to link similarities of heart disease and other disorders such as diabetes and metabolic syndrome.
According to the company, its six current clinical studies are being conducted on 90,000 patients in 40 countries to help progress treatments for cardiovascular diseases.
In addition, Merck also has developed prescription medication to aid in the treatment of various cardiovascular diseases and has provided 1.5 million prescriptions to patients who had financial hardships or were uninsured in 2008 through its patient assistance program (PAP).
Merck agreed to strengthen its ties with Actelion, Cardiome, Arena, Mochida, Portola and Xenon Pharmaceuticals to continue its assistance in the progression of cardiovascular care.